HHS Proposes COVID Vaccine Injury Compensation Table

The U.S. Department of Health and Human Services (HHS) intends to propose a COVID-19 countermeasures injury table, according to news reports from last week. This table will list specific medical conditions presumed to be caused by COVID-19 vaccines and other countermeasures. The purpose of this list is to streamline the process for individuals who suffer adverse events from these medical interventions to receive compensation.

This initiative is part of the Countermeasures Injury Compensation Program (CICP), which was established under the Public Readiness and Emergency Preparedness (PREP) Act. The PREP Act provides liability protections for manufacturers and distributors of certain medical countermeasures during public health emergencies. The CICP is designed to compensate individuals for serious physical injuries or deaths determined to have resulted from the administration of covered countermeasures.

While the specific conditions to be included in the proposed COVID-19 injury table have not yet been publicly disclosed, the process of adding conditions to the CICP table typically involves review by medical and scientific experts. The table serves as a presumptive list, meaning that if an individual's condition is on the table and they meet other eligibility criteria, the injury is presumed to be vaccine-related, simplifying the burden of proof for claimants.

Critics, however, have raised concerns about the potential inherent dangers and limitations of such tables. Some argue that the process of defining and adding conditions can be slow and may not adequately capture the full spectrum of potential vaccine injuries. Others point to the program's history, noting that the CICP has historically compensated a very small percentage of claims filed, leading to accusations of being difficult to navigate and insufficient in providing relief to those genuinely harmed. The proposed table aims to address some of these challenges for COVID-19 countermeasures specifically.